Trial Profile
A retrospective study of re-challenge with erlotinib after gefitinib in non small cell lung patients with CNS metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Dec 2015 New trial record